PRESS RELEASEAB SCIENCE PROVIDES AN UPDATE ON ITS CLINICAL PROGRAM AB SCIENCE SECURES EUR 25 MILLION CLINICAL TRIAL INSURANCE FOR ITS PHASE III ...

PROLLENIUM(R), a global leader in medical aesthetic innovation, today announced the launch of the PACE Training & Education Portal, a digital learning platform designed to expand access to the PACE ...

The state's effort will get a boost from the federal government thanks to a new executive order from President Donald Trump.

UT Health San Antonio Multispecialty and Research Hospital has enrolled and treated its first clinical trial participant in a novel cancer study, marking a pivotal moment for science and ...

Premier, Inc., a leading technology-driven healthcare improvement company, today announced the nation's 100 Top Hospitals(R) , with the full list of recognized hospitals published by Modern Healthcare ...

Dr. Lynn Kramer ’72, an executive leader, clinical neurologist, and pioneer in pharmaceutical research, will deliver a ...

Collaboration with leading European orthopedic center in Italy supports GelrinC® clinical adoptionRenowned cartilage ...

Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced updated Phase 1 (RMC-9805-001) ...

GEn1E Lifesciences Inc., a Phase 2 clinical-stage biotechnology company advancing AI-driven novel precision medicines for immunology, inflammation, and rare diseases, today announced a strategic ...

The honorees are scheduled to deliver lectures during this year’s meeting in San Diego, CA, which runs from April 17-22.

PeptiDream Inc., a public Kanagawa, Japan-based biopharmaceutical company (President: Patrick C. Reid, hereinafter “PeptiDream”) today announced that Asahi Kasei Therapeutics (Headquarters: Chiyoda-ku ...

A U.S. Senate committee has scheduled a hearing for next week on a bipartisan bill to promote research into the therapeutic ...